NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Dr. Prins was talking about partnering DCVax-l with Merck’s CI as far back as 2015. Dr. Bosch, as I already mentioned, was excited years ago that the science pointed towards synergy prospects between DCVax-l and checkpoint inhibitors which include Ketruda. Dr. Duffy came to work for NWBO from and returned back to Merck just long enough to help NWBO with SAP on Phase III and Combo design, obviously having the opportunity to conduct due diligence on DCVax-l during that time. UCLA and NWBO work together on DCVax-l and during that time, Merck and UCLA initiated the combo trial of Keytruda and DCVax-l.